Biosimilars for psoriasis: clinical studies to determine similarity

A. Blauvelt, L. Puig, S. Chimenti, R. Vender, M. Rajagopalan, R. Romiti, L. Skov, C. Zachariae, H. Young, E. Prens, A. Cohen, J. van der Walt, J. J. Wu

Research output: Contribution to journalReview articleResearchpeer-review

12 Citations (Scopus)


© 2016 British Association of Dermatologists Biosimilars are drugs that are similar, but not identical, to originator biologics. Preclinical analytical studies are required to show similarity on a molecular and structural level, but efficacy and safety studies in humans are essential to determining biosimilarity. In this review, written by members of the International Psoriasis Council, we discuss how biosimilars are evaluated in a clinical setting, with emphasis on extrapolation of indication, interchangeability and optimal clinical trial design.
Original languageEnglish
Pages (from-to)23-33
JournalBritish Journal of Dermatology
Issue number1
Publication statusPublished - 1 Jul 2017


Dive into the research topics of 'Biosimilars for psoriasis: clinical studies to determine similarity'. Together they form a unique fingerprint.

Cite this